Trials / Completed
CompletedNCT00352261
An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients
An Open-Label, 2-Way Crossover Study of Steady-State Intragastric pH Control Comparing 2 Dosage Regimens of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare the treatment of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole | |
| DRUG | Lansoprazole |
Timeline
- Start date
- 2006-01-01
- Completion
- 2007-04-01
- First posted
- 2006-07-14
- Last updated
- 2009-03-26
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00352261. Inclusion in this directory is not an endorsement.